Psoriasis

Researchers find a causal relationship between metabolic syndrome (MetS) and its components for increased risk of psoriasis.

Patients who were younger and had more disease-related skin symptoms were more likely to express interest in the intervention.

The study adds to a growing amount of literature documenting the impact of psoriasis on mental health.

People with psoriasis were also more likely to have pulmonary comorbidities compared with those who did not have psoriasis.

Authors describe 3 patients with cancer who were given interleukin-23 (IL-23) inhibitors for psoriasis or immune-related psoriasis.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for patients who have psoriasis.

Researchers laid out 6 position statements for the technology in this patient population.

However, overall fertility rates of patients with psoriasis were similar to national fertility trends, authors found.

Findings are based on a case-control study carried out in Brazil.

Findings are based on a meta-analysis of 51 studies and 739 pregnancies.

It’s estimated around 20% of patients will discontinue their first course of anti–tumor necrosis factor-α (anti–TNF-α) and rates increase over time

Although methotrexate was linked with a higher risk of anemia, it carried risks of kidney and other serious infections similar to those of biologics.

Patients with psoriasis taking methotrexate are nearly 3 times as likely to develop non-melanoma skin cancer than patients not taking the treatment.

After 1 year, overall treatment switch rates were 14.4%, while after 2 years, switch rates were 26%.

Strict inclusion and exclusion criteria in clinical trials means findings on health-related quality of life (HRQOL) may not be generalizable to the real-world setting.

Findings show these drugs were linked with a lower risk of progression to inflammatory arthritis compared with tumor necrosis factor inhibitors, although more research is needed to confirm the finding.

Approximately one quarter of patients who have psoriasis experience disease onset before adulthood.

Older people with psoriasis had a roughly 50% higher risk of being diagnosed with a malignancy, investigators found.

Ten-year mean costs associated with psoriasis-related health care visits were 10 times higher for patients with generalized pustular psoriasis (GPP).

Because biologics are used to treat both conditions, researchers hypothesized they may be helpful to prevent psoriatic arthritis (PsA).

This analysis pooled data from the reSURFACE 1 and reSURFACE 2 trials of tildrakizumab use among patients with moderate to severe plaque psoriasis.

Minority patients with skin diseases such as psoriasis often experience racial and ethnic barriers to care, a recent review found.

Dermatologists recommended biologics at similar rates in scenarios describing Black, Hispanic, and White patients with moderate to severe psoriasis.

Polypharmacy was significantly higher in patients with psoriatic arthritis when compared with controls, according to a new study.

In this new analysis, investigators found significant agreement between in-person and remote assessments.

A panel of experts provide their final thoughts on treating psoriasis across all skin phototypes.

A panel of experts provide their final thoughts on treating psoriasis across all skin phototypes.

Maria Lopes, MD, MS, and Amy McMichael, MD, discuss how payers can incentivize patients’ use of digital health tools to monitor the success or failure of treatment.

Amy McMichael, MD, provides an overview of the Psorcast app and how it can benefit treatment adherence for patients.